Traws Pharma (TRAW) news
Recent news
Traws Pharma - no revenue recognized for Q2
Traws Pharma, Inc. (NASDAQ: TRAW) is expected to report its Q2 2026 financial results on August 6, 2026, with revenue estimated at $0 . This follows a pattern of no revenue recognition in recent quarters, including Q1 2026, where the company reported $0 in revenue compared to $0.06 million in the…
AInvest Wire · Aug 14, 2026Traws Pharma Inc files for mixed shelf offering of up to $139.2 mln - filing
Traws Pharma Inc. (Nasdaq: TRAW), a clinical-stage biopharmaceutical company focused on developing antiviral therapies for respiratory diseases, has filed a mixed shelf offering of up to $139.2 million with the U.S. Securities and Exchange Commission (SEC). The offering includes sale of common…
AInvest Wire · Jul 1, 2026Traws Pharma - company expects MHRA response within 30 days of resubmission
AInvest Wire · Jun 22, 2026Traws Pharma provides updated guidance on influenza prophylaxis program
AInvest Wire · Jun 22, 2026Traws Pharma - updated data package to be resubmitted to MHRA in Q3 2026
AInvest Wire · Jun 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.